A
RARE icon

Abingworth’s Ultragenyx Pharmaceutical RARE Stock Holding History

Abingworth’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-38,100
Closed -$1.66M – 18
2018
Q4 		$1.66M Hold
38,100
– – 1.5% 12
2018
Q3 		$2.91M Hold
38,100
– – 1.73% 10
2018
Q2 		$2.93M Hold
38,100
– – 1.67% 11
2018
Q1 		$1.94M Hold
38,100
– – 1.21% 13
2017
Q4 		$1.77M Hold
38,100
– – 1.28% 13
2017
Q3 		$2.03M Buy
+38,100
New +$2.26M 1.4% 13

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Abingworth's RARE Position: Q1 2019 in Review

Abingworth sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2019, closing a stake of 38,100 shares — an estimated $1.66M sold.

Abingworth first reported a position in RARE in Q3 2017 and held it in 6 quarters. The position peaked at $2.93M in Q2 2018. 176 funds tracked by Wall St. Rank hold RARE as of Q1 2019.

  • Abingworth reported no remaining Ultragenyx Pharmaceutical position as of Q1 2019 after selling out during the quarter.
  • Abingworth sold 38,100 Ultragenyx Pharmaceutical shares in Q1 2019, an estimated $1.66M.
  • Abingworth first reported a position in Ultragenyx Pharmaceutical in Q3 2017 and held it in 6 quarters.
  • Abingworth's Ultragenyx Pharmaceutical position peaked at $2.93M in Q2 2018.
  • 176 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2019.

Based on Abingworth's 13F filing for Q1 2019, filed 15 May 2019.